GZPR(SH:600684) Chang Jiang Shang Bao·2025-09-11 08:29Core Viewpoint - Zhujiang Co., Ltd. is focusing on its core business by initiating multiple asset sales after a two-year restructuring process, aiming to optimize its asset structure and improve liquidity [1][3]. Group 1: Asset Sales - Zhujiang Co., Ltd. plans to sell shares in several companies, including 8.686 million shares of Yibai Pharmaceutical and 4.7122 million shares of Erkang Pharmaceutical, among others [1]. - The expected profit from these asset sales is projected to exceed 50% of the company's audited net profit for the last year after deducting costs and taxes [1]. - The company is also transferring debt assets worth 334 million yuan to its controlling shareholder, Zhujiang Industrial Group, as part of its strategic focus on core operations [3]. Group 2: Financial Performance - In 2024, Zhujiang Co., Ltd. reported a revenue of 1.558 billion yuan, a decrease of 52.38%, while net profit increased by 124.74% to 15.5744 million yuan [1]. - For the first half of 2025, the company achieved a revenue of 743 million yuan, a year-on-year increase of 12.02%, and net profit surged by 412.36% to 19.4782 million yuan [2]. - The company's non-recurring net profit for the first half of 2025 was 9.5033 million yuan, a decline of 57.31%, attributed to increased operating costs and a decrease in gross margin [2]. Group 3: Market Impact - The performance of Zhujiang Co., Ltd. has been significantly influenced by stock investment returns, with fluctuations in the A-share market affecting its financial results [2]. - As of June 30, 2025, the fair value of the company's stock investments was 54.4251 million yuan, with a fair value change gain of 5.2741 million yuan for the first half of 2025, contrasting with a loss of 29.4389 million yuan in the same period of 2024 [2][3].